<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13952">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353652</url>
  </required_header>
  <id_info>
    <org_study_id>413</org_study_id>
    <secondary_id>R01HL078782-02</secondary_id>
    <nct_id>NCT00353652</nct_id>
  </id_info>
  <brief_title>Evaluating the Link Between Thiazide Medications, the Nervous System, and Diabetes in Individuals With High Blood Pressure</brief_title>
  <official_title>Neural Mechanisms of Thiazide-induced Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thiazide medications are often prescribed for individuals with high blood pressure, but
      research has shown that they may increase an individual's risk of developing diabetes. While
      it is unknown exactly how thiazide causes this response, it is likely that the nervous
      system is somehow involved. This study will evaluate the role of the nervous system in sugar
      metabolism, as well as determine the effect of thiazide and other medications on individuals
      with high blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thiazide medications, including chlorthalidone, are commonly prescribed for individuals with
      high blood pressure because they are inexpensive, effective at lowering blood pressure, and
      able to reduce the risk of heart failure and stroke. Despite these advantages, research has
      shown that thiazide medications may increase an individual's risk of developing diabetes.
      The exact mechanism that causes this remains unknown. Thiazide appears to increase
      sympathetic nervous system activity, thereby decreasing glucose reuptake and metabolism by
      skeletal muscle tissues. In turn, this tends to contribute to glucose intolerance and the
      development of diabetes. More research, however, is needed to confirm this link.
      Spironolactone, another blood pressure medication, does not pose the same risk for
      developing diabetes and may prove beneficial as a primary treatment for high blood pressure.
      The purpose of this study is to determine the role of the sympathetic nervous system in
      glucose metabolism in individuals with high blood pressure, as well as compare the
      effectiveness of thiazide, spironolactone, and other antihypertensive medications in
      reducing blood pressure. Results from this study may initiate the development of future
      clinical trials involving spironolactone as a primary treatment for reducing blood pressure.

      This study will enroll individuals with high blood pressure. Participants will be assigned
      to one of eight treatment groups. Depending on the assigned group, participants will receive
      chlorthalidone, spironolactone, quinapril, irbesartan, eplerenone, or a combination of these
      drugs, with or without placebo. Participants will attend four to six study visits over a
      period of 16 to 28 weeks. All participants will attend a baseline study visit, which will
      include a physical examination, a medical history review, vital sign measurements, and blood
      and urine collection. Small electrodes will be used to measure muscle nerve activity. In
      addition, blood pressure will be monitored continuously for 24 hours prior to the start of
      the study. Depending on the assigned treatment group, study visits may include blood
      collection, blood pressure monitoring, an electrocardiogram (ECG) to record heart activity,
      nerve function monitoring, and/or plasma volume measurements. Participants' baroreflex
      sensitivity may also be measured by monitoring nerve ending responses within the heart and
      blood vessels. Insulin sensitivity will be measured with a glucose tolerance test and by
      evaluating skeletal muscle glucose uptake.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Sympathetic Nerve Activity</measure>
    <time_frame>Measured at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour Ambulatory Blood Pressure</measure>
    <time_frame>Measured at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>Measured at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Forearm Blood Flow</measure>
    <time_frame>Measured at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Baroreflex Sensitivity</measure>
    <time_frame>Measured at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive Protein</measure>
    <time_frame>Measured at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Cytokines</measure>
    <time_frame>Measured at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrolytes</measure>
    <time_frame>Measured at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Measured at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>12.5-25 mg taken orally, once daily</description>
    <arm_group_label>1A</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>50-75 mg taken orally, once daily</description>
    <arm_group_label>1A</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>50-100 mg taken orally, once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinapril</intervention_name>
    <description>20 mg taken orally, once daily</description>
    <arm_group_label>1C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>150 mg taken orally, once daily</description>
    <arm_group_label>1C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Untreated stage 1 primary hypertension (systolic blood pressure between 140 to 159 mm
             Hg and diastolic blood pressure between 90 to 99 mm Hg)

        Exclusion Criteria:

          -  Cardiopulmonary disease, as determined by medical history or by physical examination

          -  Serum creatinine greater than or equal to 1.5 mg/dL

          -  Diabetes mellitus or other systemic illness

          -  Left ventricular hypertrophy by echocardiography or ECG

          -  Hypersensitivity to chlorthalidone, spironolactone, eplerenone, angiotensin
             converting enzyme (ACE) inhibitors, angiotensin receptor blocker, insulin, Evans blue
             dye, or clonidine

          -  History of substance abuse (other than tobacco)

          -  History of gouty arthritis

          -  History of ACE inhibitor-induced cough or angioedema

          -  Evidence of secondary hypertension

          -  Pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanpen Vongpatanasin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, Southwestern Medical Center at Dallas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 16, 2014</lastchanged_date>
  <firstreceived_date>July 18, 2006</firstreceived_date>
  <firstreceived_results_date>December 2, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Wanpen Vongpatanasin</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Blood Pressure, High</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>72 subjects were screened but excluded from study because of failure to meet eligibility criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Chlorthalidone Alone</title>
          <description>Chlorthalidone: 12.5-25 mg taken orally, once daily</description>
        </group>
        <group group_id="P2">
          <title>Chlorthalidone Plus Spironolactone</title>
          <description>Chlorthalidone: 12.5-25 mg taken orally, once daily
Spironolactone: 50-75 mg taken orally, once daily</description>
        </group>
        <group group_id="P3">
          <title>Chlorthalidone Plus Irbesartan</title>
          <description>Chlorthalidone: 12.5-25 mg taken orally, once daily
Irbesartan: 150 mg taken orally, once daily</description>
        </group>
        <group group_id="P4">
          <title>Irbesartan</title>
          <description>Drug: Irbesartan
150 mg taken orally, once daily</description>
        </group>
        <group group_id="P5">
          <title>Chlorthalidone</title>
          <description>Chlorthalidone 12.5-25 mg taken orally daily</description>
        </group>
        <group group_id="P6">
          <title>Spironolactone</title>
          <description>Spironolactone 25-75 mg taken orally daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chlorthalidone Alone</title>
          <description>Chlorthalidone: 12.5-25 mg taken orally, once daily</description>
        </group>
        <group group_id="B2">
          <title>Chlorthalidone Plus Spironolactone</title>
          <description>Chlorthalidone: 12.5-25 mg taken orally, once daily
Spironolactone: 50-75 mg taken orally, once daily</description>
        </group>
        <group group_id="B3">
          <title>Chlorthalidone Plus Irbesartan</title>
          <description>Chlorthalidone: 12.5-25 mg taken orally, once daily
Irbesartan: 150 mg taken orally, once daily</description>
        </group>
        <group group_id="B4">
          <title>Irbesartan</title>
          <description>Drug: Irbesartan
150 mg taken orally, once daily</description>
        </group>
        <group group_id="B5">
          <title>Chlorthalidone</title>
          <description>Chlorthalidone: 12.5-25 mg taken orally, once daily</description>
        </group>
        <group group_id="B6">
          <title>Spironolactone</title>
          <description>Spironolactone: 25-75 mg taken orally, once daily</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="7"/>
                <measurement group_id="B5" value="23"/>
                <measurement group_id="B6" value="23"/>
                <measurement group_id="B7" value="104"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50.6" spread="2.3"/>
                <measurement group_id="B2" value="50.6" spread="2.3"/>
                <measurement group_id="B3" value="50.6" spread="2.3"/>
                <measurement group_id="B4" value="47" spread="3"/>
                <measurement group_id="B5" value="51" spread="2"/>
                <measurement group_id="B6" value="51" spread="2"/>
                <measurement group_id="B7" value="50.5" spread="2.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="2"/>
                <measurement group_id="B5" value="9"/>
                <measurement group_id="B6" value="9"/>
                <measurement group_id="B7" value="38"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="5"/>
                <measurement group_id="B5" value="14"/>
                <measurement group_id="B6" value="14"/>
                <measurement group_id="B7" value="66"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="7"/>
                <measurement group_id="B5" value="23"/>
                <measurement group_id="B6" value="23"/>
                <measurement group_id="B7" value="104"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sympathetic Nerve Activity</title>
        <time_frame>Measured at 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Chlorthalidone Alone</title>
            <description>Chlorthalidone: 12.5-25 mg taken orally, once daily</description>
          </group>
          <group group_id="O2">
            <title>Chlorthalidone Plus Spironolactone</title>
            <description>Chlorthalidone: 12.5-25 mg taken orally, once daily
Spironolactone: 50-75 mg taken orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Chlorthalidone Plus Irbesartan</title>
            <description>Chlorthalidone: 12.5-25 mg taken orally, once daily
Irbesartan: 150 mg taken orally, once daily</description>
          </group>
          <group group_id="O4">
            <title>Spironolactone</title>
            <description>Spironolactone 25-50 mg taken orally daily</description>
          </group>
          <group group_id="O5">
            <title>Chlorthalidone</title>
            <description>Chlorthalidone 12.5-25 mg taken orally</description>
          </group>
          <group group_id="O6">
            <title>Irbesartan</title>
            <description>Irbesartan 150 mg taken orally once a day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="18"/>
                  <measurement group_id="O5" value="18"/>
                  <measurement group_id="O6" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sympathetic Nerve Activity</title>
            <units>bursts/min</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="49" spread="4"/>
                  <measurement group_id="O2" value="42" spread="3"/>
                  <measurement group_id="O3" value="52" spread="2"/>
                  <measurement group_id="O4" value="37" spread="2"/>
                  <measurement group_id="O5" value="45" spread="3"/>
                  <measurement group_id="O6" value="46" spread="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>24-hour Ambulatory Blood Pressure</title>
        <time_frame>Measured at 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity</title>
        <time_frame>Measured at 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Forearm Blood Flow</title>
        <time_frame>Measured at 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baroreflex Sensitivity</title>
        <time_frame>Measured at 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C-reactive Protein</title>
        <time_frame>Measured at 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammatory Cytokines</title>
        <time_frame>Measured at 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrolytes</title>
        <time_frame>Measured at 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight</title>
        <time_frame>Measured at 6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Chlorthalidone Alone</title>
          <description>Chlorthalidone: 12.5-25 mg taken orally, once daily</description>
        </group>
        <group group_id="E2">
          <title>Chlorthalidone Plus Spironolactone</title>
          <description>Chlorthalidone: 12.5-25 mg taken orally, once daily
Spironolactone: 50-75 mg taken orally, once daily</description>
        </group>
        <group group_id="E3">
          <title>Chlorthalidone Plus Irbesartan</title>
          <description>Chlorthalidone: 12.5-25 mg taken orally, once daily
Irbesartan: 150 mg taken orally, once daily</description>
        </group>
        <group group_id="E4">
          <title>Irbesartan</title>
          <description>Drug: Irbesartan 150 mg taken orally, once daily</description>
        </group>
        <group group_id="E5">
          <title>Chlorthalidone</title>
          <description>Chlorthalidone 12.5-25 mg taken orally daily</description>
        </group>
        <group group_id="E6">
          <title>Spironolactone</title>
          <description>Spironolactone 25-75 mg taken orally daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wanpen Vongpatanasin</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>2146458000</phone>
      <email>wanpen.vongpatanasin@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
